Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

NCT00246974 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00246974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00246974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2003
Completion date
December 31, 2007
Enrollment
125 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer